Vaccine Characterization Using Advanced Technology - Mass spectrometry offers the potential for an unprecedented understanding of vaccines and why they fail. - BioPharm International

ADVERTISEMENT

Vaccine Characterization Using Advanced Technology
Mass spectrometry offers the potential for an unprecedented understanding of vaccines and why they fail.


BioPharm International


7. Gavin D. Perspectives on potency assays for complex biological products. 2007 WCBP, CMC Forum on Bioassays, 2007 Jan 28; Washington, DC.

8. WHO. Immunization, vaccines and biologicals: strategic plan 2006–2009. Geneva: 2005 Dec.

9. WHO. Recommendations for the preparation, characterization and establishment of international and other biological reference standards, final draft. Adopted by the 55th meeting of the WHO expert committee on biological standardization. Geneva: 2004 Nov 15–18.

10. International Conference on Harmonization. Q6B, Specifications: Test procedures and acceptance criteria for biotechnological/biological products. Geneva, Switzerland:1999 Mar 10.

11. ICH. Q5C, Quality of biotechnological products: stability testing of biotechnological/biological products. Geneva: 1995 Nov 30.

12. ICH. Q5D, Derivation and characterization of cell substrates used for production of biotechnological/biological products. Geneva: 1997 July 16.

13. ICH. Q5E, Comparability of biotechnological/biological products subject to changes in their manufacturing process.Geneva: 2004 Nov 18.

14. Girard MP et al. A review of human vaccine research and development: Malaria. Vaccine. 2007; 25:1567–1580.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Novartis and GSK Trade Assets
April 22, 2014
Lilly to Acquire Novartis Animal Health
April 22, 2014
EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here